Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial

Authors: Stéphane Palfi, Jean Marc Gurruchaga, G. Ralph, H. Lepetit, Sonia Lavisse, Philip C. Buttery, Colin Watts, James Miskin, Michelle Kelleher, Sarah Deeley, Hirokazu Iwamuro, Jean Pascal Lefaucheur, Claire Thiriez, Gilles Fénelon, Cherry Lucas, Pierre Brugières, Inanna Gabriel, K Abhay, Xavier Drouot, Naoki Tani, Aurélie Kas, Bijan Ghaleh, Philippe Le Corvoisier, Patrice Dolphin, David P Breen, Sarah Mason, Natalie Valle Guzman, Nicholas D. Mazarakis, Pippa A. Radcliffe, Richard Harrop, Susan M. Kingsman, Olivier Rascol, Stuart Naylor, Roger A. Barker, Philippe Hantraye, Philippe Rémy, Pierre Césaro, Kyriacos Mitrophanous - The Lancet 2014 cited by 436